Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy
about
Cancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant StateMetastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapyFrom bench to bedside: immunotherapy for prostate cancerImmunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implicationsBeyond the androgen receptor: new approaches to treating metastatic prostate cancer. Report of the 2013 Prouts Neck Prostate Cancer MeetingCombining T-cell immunotherapy and anti-androgen therapy for prostate cancer.Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation.The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer.Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer.Prostate cancer vaccines in combination with additional treatment modalities.Castration-resistant prostate cancer: latest evidence and therapeutic implications.Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies.Prostate cancer vaccines: the long road to clinical application.Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse.Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting.Immunotherapy for prostate cancer enters its golden age.Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer.
P2860
Q26782573-D9164E5C-7F0D-4801-8466-42E1D8735993Q26825053-3376DC36-ECAA-4971-82F4-C96AF1BD7DC9Q26864390-F58FAFFE-617B-4F95-A0F7-8C415246451CQ33621393-717EC62E-2B22-48F0-B19B-867C0C5DAE37Q34617627-FDD38D62-5F68-481F-9C82-16F5E9E502EDQ37443603-25380BF7-1C9F-4172-A314-9B29F44BB195Q38088635-3555C5DD-41CA-4D6A-BE7E-6FBB4F39B855Q38203779-D9ECFB1E-F435-4C13-B66B-F74613844DDAQ38205964-4D9E3F60-3140-473B-8CE2-2A528994700FQ38212571-0FECF1AE-5B03-47B9-8832-96C6402F04F1Q38233358-06F043E3-F2E8-4C60-904D-6B992407DD70Q38248440-7692207B-00BC-4ABE-AF3A-88988ED9F041Q38359237-49CF1658-7820-43AD-932F-F8B5E852E933Q38780080-96623157-C695-4BE6-88F9-6E3DB913CC1DQ38966736-55F2FA2A-75E9-4699-AFEA-21DDAEC524ADQ39577914-7CE1E936-95BF-45D1-AA71-236656863AC5Q41906005-4F9FAC3B-03F6-4D1E-994B-C46820660D4D
P2860
Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy
description
2012 nî lūn-bûn
@nan
2012 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Combining immunological and an ...... prostate cancer immunotherapy
@ast
Combining immunological and an ...... prostate cancer immunotherapy
@en
Combining immunological and an ...... prostate cancer immunotherapy
@nl
type
label
Combining immunological and an ...... prostate cancer immunotherapy
@ast
Combining immunological and an ...... prostate cancer immunotherapy
@en
Combining immunological and an ...... prostate cancer immunotherapy
@nl
prefLabel
Combining immunological and an ...... prostate cancer immunotherapy
@ast
Combining immunological and an ...... prostate cancer immunotherapy
@en
Combining immunological and an ...... prostate cancer immunotherapy
@nl
P2860
P1476
Combining immunological and an ...... prostate cancer immunotherapy
@en
P2093
Charles G Drake
P2860
P304
P356
10.1097/CCO.0B013E32835205A0
P407
P577
2012-05-01T00:00:00Z